Sessions are scheduled in local time (CEST)
Exhibition area
Poster Display session
Date
Thu, 16.05.2024
Room
Exhibition area
Time
12:00 - 13:00
Lunch and Poster Display session (ID 48)
6P - HbA1c as a prognostic biomarker in early breast cancer among patients without diabetes (ID 542)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jonas B. Holm (Aarhus, Denmark)
Lunch and Poster Display session (ID 48)
7P - Trastuzumab deruxtecan (T-DXd) for Advanced Breast Cancer (ABC) patients (pts), regardless of HER2 status: a phase II study with Biomarkers Analysis (DAISY). Update analysis with longer follow-up. (ID 504)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Veronique C. Dieras (Rennes, France)
Lunch and Poster Display session (ID 48)
8P - Evaluating HER2DX pCR-Score and MRI response in predicting pathologic complete response (pCR) to anti-HER2 neoadjuvant chemotherapy (CT) in early-stage HER2-positive (HER2+) breast cancer (BC) (ID 383)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tomás Pascual (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
9P - Plasticity marker FOXC1 expression is a superior predictor of Adjuvant Tamoxifen + Chemotherapy efficacy in reducing disease recurrence and all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096) (ID 1019)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Partha S. Ray (Lincolnwood, United States of America)
Lunch and Poster Display session (ID 48)
10P - PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy – a biomarker study of the LORELEI trial (ID 468)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Danai Fimereli (Brussels, Belgium)
Lunch and Poster Display session (ID 48)
11P - Influence of ctDNA Variant Allele Frequency (VAF) on Survival Outcomes in Metastatic Breast Cancer (MBC) (ID 424)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Isabel Garcia Fructuoso (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
12P - Updated findings from the first prospective HER2DX clinical decision impact study on early-stage HER2-positive (HER2+) breast cancer (BC) (ID 727)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Olga Martínez-Sáez (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
13P - HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive (HER2+) Breast Cancer (BC): Implications for Treatment Stratification (ID 637)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Rodrigo Sanchez Bayona (Madrid, Spain)
Lunch and Poster Display session (ID 48)
14P - Assessing the Predictive Value of HER2DX pCR-Score for Pathologic Complete Response (pCR) in Early-Stage HER2-Positive (HER2+) Breast Cancer (BC) Under Real-World Conditions (ID 721)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Olga Martínez-Sáez (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
16P - Determinants of response to short preoperative endocrine therapy (pET) in hormone receptor-positive and HER2-negative (HR+/HER2-) early breast cancer (EBC) (ID 399)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Raquel Gómez Bravo (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
17P - Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy (ID 429)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Brendah K. Masisi (Gaborone, Botswana)
Lunch and Poster Display session (ID 48)
18P - Prognostic significance of complete cell cycle arrest in patients with HR+HER2- breast cancer receiving neoadjuvant chemotherapy (ID 470)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sung Gwe Ahn (Seoul, Korea, Republic of)
Lunch and Poster Display session (ID 48)
19P - HER2-Low prognosis in early breast cancer a canto based study (LILAC) (ID 473)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lauriane DURAND (Caen, Cedex 5, France)
Lunch and Poster Display session (ID 48)
20P - Prognostic implications of IGF-1R expression in breast cancer overall and across body mass index groups (ID 544)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jonas B. Holm (Aarhus, Denmark)
Lunch and Poster Display session (ID 48)
21P - Tumor cell expressed SDC1 in breast cancer and breast cancer patient survival. (ID 594)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Song Yao (Shanghai, China)
Lunch and Poster Display session (ID 48)
22P - Unveiling biological and prognostic differences among premenopausal patients with hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (ID 622)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Benjamin Walbaum (Santiago, Chile)
Lunch and Poster Display session (ID 48)
23P - Longitudinal Evaluation of PAM50 Molecular Subtypes in Patients Receiving Neoadjuvant HER2-targeted Therapy in the PREDIX HER2 Trial (ID 782)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Emmanouil G. Sifakis (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
24P - Letrozole and exemestane as serum estrogen suppressors during neoadjuvant therapy in breast cancer patients: a head-to-head comparison (ID 476)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jürgen Geisler (Lorenskog, Norway)
Lunch and Poster Display session (ID 48)
25P - Immune Checkpoint gene expression in Breast Carcinoma: Correlation with Clinicopathological features and prognostic value (ID 751)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Yoel Genaro Montoyo-Pujol (Alicante, Spain)
Lunch and Poster Display session (ID 48)
26P - Lipidic and T-cell characterization as prognostic biomarkers for patients with ER+ HER2- metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK4/6i) (ID 766)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Letizia Negrini (Vercelli, Italy)
Lunch and Poster Display session (ID 48)
27P - Impact of chemotherapy (CT) use and stromal Tumor-Infiltrating Lymphocytes (sTILs) in Stage I Triple Negative Breast Cancer (TNBC) (ID 593)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Vittoria Barberi (Latina, Italy)
Lunch and Poster Display session (ID 48)
28P - The Ki67 proliferation index in subtypes of human DCIS grade 3 - a biomarker with potential impact on clinical decision making? (ID 372)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Hossein Schandiz (Oslo, Norway)
Lunch and Poster Display session (ID 48)
29P - Long-term performance of Residual Cancer Burden (RCB), Clinical Pathological Stage (CPS) and CPS+ER+Grade (CPS-EG) models in ER+HER2- breast cancer (BC) patients (pts) after neoadjuvant chemotherapy (NAC): Role of Ki67 drop and extended endocrine therapy (EET) (ID 767)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lucia Sanz Gomez (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
30P - E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma (ID 308)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lounes Djerroudi (Paris, France)
Lunch and Poster Display session (ID 48)
31P - Crown-like structures are associated with changes in immune cell infiltrates and gene signatures in patients with primary invasive breast cancer (ID 351)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Constantinos Savva (Southampton, Nottinghamshire, United Kingdom)
Lunch and Poster Display session (ID 48)
32P - Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers – A FLEX sub study (ID 578)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Virginia F. Borges (Aurora, United States of America)
Lunch and Poster Display session (ID 48)
33P - Breast cancer brain metastases present a suppressed immune microenvironment enriched in macrophagic components as compared to paired primary tumors (ID 732)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Gaia Griguolo (Padova, Italy)
Lunch and Poster Display session (ID 48)
34P - Premenopausal Breast Cancer and CYP27A1 expression - a Cholesterol-associated Biomarker (ID 1003)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jeppe Skovbjerg (Aarhus, Denmark)
Lunch and Poster Display session (ID 48)
35P - Genomic and Clinical Landscape of Metastatic Hormone Receptors-positive Breast Cancers carrying ESR1 Alterations (ID 680)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Luca Boscolo Bielo (Milan, Italy)
Lunch and Poster Display session (ID 48)
36P - Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping and Prognostic Classification (ID 717)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Evan D. Paul (Bratislava, Slovak Republic)
Lunch and Poster Display session (ID 48)
37P - Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit (ID 506)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Joanna Gorniak (Manchester, United Kingdom)
Lunch and Poster Display session (ID 48)
38P - Spatial analysis of the tumor microenvironment in hormone receptor-positive (HR+) young women breast cancer (YWBC) from a parity and lactation perspective. (ID 758)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Miriam Sanso (Palma, Spain)
Lunch and Poster Display session (ID 48)
39P - Genomic landscape of metaplastic breast cancer from the AACR GENIE database (ID 835)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Parth Sharma (Kansas City, United States of America)
Lunch and Poster Display session (ID 48)
40P - A peculiar chromosome 17 copy number profile stratifies HER2-low breast carcinomas (ID 861)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sara E. Bellomo (Torino, Italy)
Lunch and Poster Display session (ID 48)
42P - DPD testing from tumor RNAseq in breast cancer: a proof of concept analysis (ID 1010)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Kristín Sigurjónsdóttir (Lund, Sweden)
Lunch and Poster Display session (ID 48)
43P - Deciphering Spatial Expression of Trop-2, HER2, and AR: Towards Customized Treatments in Triple-Negative Breast Cancer (ID 1048)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Marcela Carausu (Anderlecht, Belgium)
Lunch and Poster Display session (ID 48)
44P - Metaplastic Breast Cancer: Decoding the Molecular Puzzle and Immune Interplay – A Single-Center Experience (ID 759)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Anna Lea Amylidi (Ioannina, Greece)
Lunch and Poster Display session (ID 48)
45P - Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 Inhibitors. (ID 776)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Cristina Guarducci (Firenze, Italy)
Lunch and Poster Display session (ID 48)
46P - Radiogenomic analysis of breast cancer according to the adjacent parenchymal tissue by using RNA sequencing: Association with background parenchymal enhancement and peritumoral edema on breast MRI. (ID 777)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tae Hee Kim (Suwon, Korea, Republic of)
Lunch and Poster Display session (ID 48)
47P - Digital Spatial Profiling Reveals Age-Related Disparities in Immune Microenvironment and Aggressive Phenotypes in Triple-Negative Breast Cancer (ID 887)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Snijesh V P (Bangalore, India)
Lunch and Poster Display session (ID 48)
48P - Large-scale DNA organization of nuclei in DCIS ducts with adjacent invasive cancer (ID 456)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Martial D. Guillaud (Vancouver, Canada)
Lunch and Poster Display session (ID 48)
49P - A ctDNA Tool for Identifying ESR1-Mutated Biology in ESR1-non-Mutated Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC) (ID 357)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Isabel Garcia Fructuoso (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
50P - Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: analysis of the phase 2 GIADA trial (ID 591)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Maria Vittoria Dieci (Padova, Italy)
Lunch and Poster Display session (ID 48)
51P - ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study. (ID 941)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Karthik Giridhar (Rochester, United States of America)
Lunch and Poster Display session (ID 48)
52P - Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling (ID 930)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Federica Giugliano (Villejuif, Cedex, France)
Lunch and Poster Display session (ID 48)
53P - Longitudinal ctDNA Surveillance in Older Women With ER+ Breast Cancer Who Omit Surgery and Receive Primary Endocrine Therapy (ID 598)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Steffi Oesterreich (Pittsburgh, PA, United States of America)
Lunch and Poster Display session (ID 48)
54P - Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment (ID 712)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Eva Valentina V. Klocker (Graz, Austria)
Lunch and Poster Display session (ID 48)
55P - Landscape of PIK3CA, PTEN, and AKT1 alterations in advanced breast cancer (ABC) using circulating tumor DNA (ctDNA) Next Generation Sequencing (NGS) in Asia and the Middle East (AME) (ID 746)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Shaheenah Dawood (Dubai, United Arab Emirates)
Lunch and Poster Display session (ID 48)
56P - Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: a secondary analysis of the phase II PREDIX HER2 trial (ID 866)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- I. Zerdes (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
57P - Intrinsic and acquired blood-based tumor mutational burden in metastatic ER+/HER2- breast cancer treated with endocrine therapy and a CDK4/6-inhibitor (ID 881)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mitchell Elliott (Toronto, Canada)
Lunch and Poster Display session (ID 48)
58P - Soluble immune checkpoints as a promising avenue for breast cancer stratified by molecular subtype (ID 243)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Banu Yigit (Istanbul, Turkey)
Lunch and Poster Display session (ID 48)
59P - Potential of AKT1, ERBB2, ESR1, KRAS, PIK3CA and TP53 alterations detected by a new NGS assay on liquid biopsy predictive of early response/resistance to hormonal therapy and CDK4/6 inhibitors. (ID 602)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sara Bravaccini (Forlì, Italy)
Lunch and Poster Display session (ID 48)
60P - Expression of antibody-drug conjugate targets in metastatic breast cancer (ID 272)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Kristien Borremans (Leuven, Belgium)
Lunch and Poster Display session (ID 48)
61P - In-situ Generation of Cancer Antigens with ProLonged TLR7/8 Agonist Immunomodulator for Cancer Therapy in Preclinical Model (ID 422)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Chul Kim (Seoul, Korea, Republic of)
Lunch and Poster Display session (ID 48)
62P - Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort (ID 627)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Gudbjörg R. Sigurjonsdottir (Lund, Sweden)
Lunch and Poster Display session (ID 48)
63P - Enhancing HER2 Evaluation: Correlation between APIS Breast Cancer Subtyping Kit and IHC/ISH for Accurate HER2 Quantification (ID 636)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Joanna Gorniak (Manchester, United Kingdom)
Lunch and Poster Display session (ID 48)
65P - Multi-site European Study of a Fully Automated Artificial Intelligence Solution for HER2 IHC Scoring in Breast Cancer (ID 481)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Joanna Cyrta (Paris, France)
Lunch and Poster Display session (ID 48)
66P - Evaluation of an artificial intelligence algorithm for automated PD-L1 CPS scoring in triple-negative breast cancer across institutions, scanners, and antibody clones. (ID 936)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Patrick Frey (Hamburg, Germany)
Lunch and Poster Display session (ID 48)
67P - Artificial Intelligence to predict early progressors among aBC patients treated with first-line CDK4/6i: a sub-analysis from PALMARES-2 study (ID 611)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Leonardo Provenzano (Milan, Italy)
Lunch and Poster Display session (ID 48)
68P - Application of a Machine Learning Model for Identifying an Ultra-low Risk Group of Early Breast Cancer Patients (ID 728)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Michail Sarafidis (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
69P - Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides (ID 228)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Nikos Tsiknakis (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
70P - Development and Validation of a Machine Learning (ML) Nomogram to Predict RSClin Results and Guide Adjuvant Treatment of Node-negative (N0) Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor Negative (HER2-) Early Breast Cancer (eBC) in Europe. (ID 502)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Flavia Jacobs (Milan, Italy)
Lunch and Poster Display session (ID 48)
71P - Patient-reported understanding of biomarkers associated with metastatic breast cancer (mBC) diagnosis: results from a global mBC survey in 36 countries (ID 298)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Eva Schumacher-Wulf (Köln, Germany)
Lunch and Poster Display session (ID 48)
72P - A Cost-Consequence Model Assessing Gene Expression Tests Among Early-Stage Breast Cancer Patients in Belgium (ID 263)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Caroline Charles (Montpellier, Cedex 5, France)
Lunch and Poster Display session (ID 48)
73P - Real world analysis of the use of the 21-gene assay in prognostically intermediate luminal breast cancer (BC): experience from a French multicenter cohort (ID 471)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Bruno Cutuli (Reims, France)
Lunch and Poster Display session (ID 48)
74P - Assessing the Implementation of the HER2DX Genomic Test in a Real-World Setting for HER2-Positive Breast Cancer (ID 837)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Juan Miguel Cejalvo (Valencia, Valencia, Spain)
Lunch and Poster Display session (ID 48)
75P - A multicenter physician survey evaluating Ki-67 use in breast cancer management in Canada (ID 740)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jennifer Leigh (Ottawa, Canada)
Lunch and Poster Display session (ID 48)
76P - Pegylated Immunoliposome encapsulating docetaxel: In Vitro Activity and Optimal Pharmacokinetics in a breast cancer model (ID 805)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mathilde Dacos (Marseille, Cedex 07, France)
Lunch and Poster Display session (ID 48)
77P - Breast cancer pharmacogenetics in Botswana (ID 309)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Keneuoe C. Nthontho (Gaborone, Botswana)
Lunch and Poster Display session (ID 48)
78P - Tumor educated platelets promote disease advancement in breast cancer by interacting with cancer stem cells (ID 479)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Aishwarya Guha (Kolkata, India)
Lunch and Poster Display session (ID 48)
79P - 3D Matrix Models and Multi-Organ Chip platform for advancing the investigation of breast cancer dynamics and Bone Metastasis in vitro (ID 913)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Silvia Scaglione (genoa, Italy)
Lunch and Poster Display session (ID 48)
80P - Is there a link between crown-like structures and tumour-associated macrophages in patients with HER2+ breast cancer? (ID 568)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sophie Raffray (Southampton, United Kingdom)
Lunch and Poster Display session (ID 48)
81P - Exosomal HMGB1 induce PD-L1+-tumor associated macrophages via glycometabolic reprogramming to promote lung-tropic metastasis of triple negative breast cancer (ID 305)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Wei-xian Chen (Changzhou, China)
Lunch and Poster Display session (ID 48)
82P - VRTX531, a Potent Inhibitor of USP1 for Treatment of BRAC1/2mut and HRD+ cancers (ID 630)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Uday K. Surampudi (Cambridge, United States of America)
Lunch and Poster Display session (ID 48)
83P - Boron-doped alginate carbon-nanogels exhibits superior anti-metastatic effect on breast cancer by cell cycle arrest and actin dysfunction (ID 146)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Saumyadip Sarkar (Keelung City, Taiwan)
Lunch and Poster Display session (ID 48)
84P - Investigating the Activation of Brain-derived Neurotrophic Factor (BDNF)-Tropomyosin receptor kinase B (TrkB) Pathway in Breast Cancer Brain Metastasis (ID 984)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jieun Lee (Seoul, Korea, Republic of)
Lunch and Poster Display session (ID 48)
85P - Is omitting axillary lymph node dissection applicable to all Z0011-eligible breast cancer patients? (ID 501)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Xinyu Li (Guangzhou, China)
Lunch and Poster Display session (ID 48)
86P - The value of intraoperative frozen section examination in the survival of breast cancer (ID 933)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Anne W. Zhu (Vienna, Austria)
Lunch and Poster Display session (ID 48)
87P - Locoregional response and type of axillary surgery in patients who received neoadjuvant systemic therapy (NST): A Retrospective multicenter analysis of 720 patients (ID 863)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Vesna Bjelic-Radisic (Wuppertal, Germany)
Lunch and Poster Display session (ID 48)
88P - Bilateral Mastectomy and Breast Cancer Mortality (ID 329)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Vasily Giannakeas (Toronto, Canada)
Lunch and Poster Display session (ID 48)
89P - BIMAP: Breast cancer Intra-operative Margin Assessment using PET-CT (ID 234)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Anne-Sofie De Crem (Gent, Belgium)
Lunch and Poster Display session (ID 48)
90P - Where is the Balance of Benefit: Blue Dye Anaphylaxis Versus Sentinel Node Understaging? (ID 1021)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Danayan Luxmanan (Southampton, United Kingdom)
Lunch and Poster Display session (ID 48)
92P - Sentinel Lymph Node Biopsy for Local Recurrence of Breast Cancer (ID 490)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Elizaveta A. Golovina (Moscow, Russian Federation)
Lunch and Poster Display session (ID 48)
93P - Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world study (ID 540)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Wenhui Guo (Fuzhou, Fujian, China)
Lunch and Poster Display session (ID 48)
94P - Biological Effects of a Pre-Operative Radiotherapy Boost in Early-Stage Breast Cancer: Primary Results of the YOUNGSTER Unicentric Single-Arm Clinical Trial (ID 802)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Fara Brasó-Maristany (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
95P - Omission of postoperative radiation therapy in older patients with low-risk breast cancer treated with breast-conserving surgery: long-term results of the KohoRT study (ID 405)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sofia Palmér (Örebro, Sweden)
Lunch and Poster Display session (ID 48)
96P - Intraoperative radiological control of resection margins after neoadjuvant systemic therapy in breast-conserving surgery in patients with breast cancer (ID 724)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Yana Bondarchuk (Saint-Petersburg, Russian Federation)
Lunch and Poster Display session (ID 48)
97P - The impact of updated imaging software on the performance of machine learning models for breast cancer diagnosis. A multi-center, retrospective study (ID 624)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lie Cai (Heidelberg, Germany)
Lunch and Poster Display session (ID 48)
98P - The added value of whole-body diffusion weighted MRI (WB-DWI/MRI) in staging invasive lobular carcinoma (ID 909)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Karen Van Baelen (Leuven, Belgium)
Lunch and Poster Display session (ID 48)
99P - Development of a Risk Assessment and Prediction Model for DCIS Recurrence: Insights from Analysis of 600 Patients (ID 463)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Warachya Arjhan (Bangkok, Thailand)
Lunch and Poster Display session (ID 48)
100P - Diagnostic value of CT-scan and ultrasound for axillary lymph node staging in early breast cancer (ID 819)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tetiana S. Shevchuk (Kiev, Ukraine)
Lunch and Poster Display session (ID 48)
101P - Correlation of Radiological and Pathologic Lymph Nodes Status After Neoadjuvant Treatment of Early HER2-positive Breast Cancer (ID 962)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Alexander V. Petrovsky (Moscow, Russian Federation)
Lunch and Poster Display session (ID 48)
102P - The impact of multiparametric whole-body magnetic resonance imaging on Breast Cancer management: a prospective study (ID 1045)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Filippo Merloni (Meldola, Italy)
Lunch and Poster Display session (ID 48)
103P - PET-CT in localized breast cancer: Does it impact on the therapeutic decision? (ID 1014)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Paula Macias Rodriguez (Seville, Spain)
Lunch and Poster Display session (ID 48)
104P - Quantification Analysis of Low-Cost Near Infrared Camera for Breast Cancer Treatment-Related Lymphedema Fluorescence Imaging (ID 256)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Bayu Brahma (West Jakarta, Indonesia)
Lunch and Poster Display session (ID 48)
105P - Impact of the number of synchronous cancer lesions in Bulgarian patients with multiple breast cancer (ID 848)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Slavyana S. Usheva (Sofia, Bulgaria)
Lunch and Poster Display session (ID 48)
106P - Incorporating Religious and Cultural Background: Patient Informed Consent in the Era of Acellular Dermal Matrix Breast Reconstruction (ID 450)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jose A. Foppiani (Boston, United States of America)
Lunch and Poster Display session (ID 48)
107P - Clinicopathologic Features of Breast Cancer Patients in a Single Tertiary Hospital in the Philippines (ID 515)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Maria Carmela Y. Vistal (Quezon City, Philippines)
Lunch and Poster Display session (ID 48)
108TiP - CINDERELLA Clinical Trial (NCT05196269): using artificial intelligence-driven healthcare to enhance breast cancer locoregional treatment decisions (ID 288)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Andre Pfob (Heidelberg, Germany)
Lunch and Poster Display session (ID 48)
114P - Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre Phase III (neo)adjuvant FeDeriCa study (ID 917)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Christian Jackisch (Offenbach am Main, Germany)
Lunch and Poster Display session (ID 48)
115P - Neoadjuvant pyrotinib combined with trastuzumab, albumin paclitaxel, and carboplatin for HER2-positive early or locally advanced breast cancer: a single-arm phase II trial (ID 710)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mei Liu (Chongqing, China)
Lunch and Poster Display session (ID 48)
116P - Interim analysis of 300 patients with HER2+/HR+ early breast cancer enrolled in the multi-national, prospective, observational ELEANOR NIS treated with extended adjuvant neratinib in clinical routine (ID 374)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Rupert Bartsch (Vienna, Austria)
Lunch and Poster Display session (ID 48)
117P - Three-year invasive disease-free survival results from a phase 2 study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer (ID 457)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Dan Zheng (Chengdu, China)
Lunch and Poster Display session (ID 48)
118P - A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer in China: NER-Tree study—An interim analysis on patient characteristics and pretreatment patterns (ID 247)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jin Zhang (Tianjin, He Xi District, China)
Lunch and Poster Display session (ID 48)
119P - HER2+ early-stage breast cancer treated with extended adjuvant neratinib in the context of the European Early Access Program: NEAR study final results (ID 533)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tajana Silovski (Zagreb, Croatia)
Lunch and Poster Display session (ID 48)
120P - Impact of PET-CT and neoadjuvant systemic treatment in patients with stage I HER2+ breast cancer (ID 966)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Josefien P. Van Olmen (Amsterdam, Netherlands)
Lunch and Poster Display session (ID 48)
121P - Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial (ID 1058)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Moritz Hamann (Munich, Germany)
Lunch and Poster Display session (ID 48)
122P - Primary results and biomarker analysis from PREDIX Lum B, a prospective randomized phase 2 trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer (ID 461)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Alexios Matikas (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
123P - Goserelin 10.8 mg and 3.6 mg Depots in Breast Cancer (BC): A Large Real-World Noninferiority Study (ID 491)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Yongsheng Wang (Jinan, China)
Lunch and Poster Display session (ID 48)
124P - Neoadjuvant Durvalumab plus Endocrine Therapy following Immunoattractant Exposure for early-stage ER+/HER2– breast cancer (ID 503)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Benjamin Verret (Villejuif, France)
Lunch and Poster Display session (ID 48)
125P - Suboptimal ovarian suppression during adjuvant endocrine therapy for premenopausal women with breast cancer: an exploratory analysis of the PREFER and GIM 23 studies (ID 832)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Simone Nardin (Genova, Italy)
Lunch and Poster Display session (ID 48)
126P - A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study]. (ID 872)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Marie-France Savard (Ottawa, Canada)
Lunch and Poster Display session (ID 48)
127P - Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial (ID 919)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jens Huober (St. Gallen, Switzerland)
Lunch and Poster Display session (ID 48)
129P - Adherence to Adjuvant Endocrine Therapy in the Era of Combination Treatments – a Population-Based Study (ID 749)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Louise Eriksson Bergman (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
130P - Progesterone receptor（PR）status and survival outcomes of ER-negative breast cancer: a population-based cohort study (ID 316)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lv Wenjie (Shanghai, China)
Lunch and Poster Display session (ID 48)
131P - Efficacy and Safety of Different Dosage Forms of Gonadotropin Releasing Hormone Agonists Combined with Selective Estrogen Receptor Modulators or Aromatase Inhibitors in Premenopausal Hormone Receptor-Positive Breast Cancer Patients (ID 354)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jinna Lin (Guangzhou, China)
Lunch and Poster Display session (ID 48)
132P - Clinico-pathological characteristics, treatments and survival outcomes of patients with high-risk hormone receptor positive early breast cancer (HR+ BC) in French Real World (RW) setting: a study from CANTO cohort (ID 494)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Federica Giugliano (Villejuif, Cedex, France)
Lunch and Poster Display session (ID 48)
133P - Clinico-pathological predictors of outcome in the (neo)adjuvant setting of luminal/HER2-negative Invasive Lobular breast Cancer (ILC) (ID 570)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Luisa Carbognin (Rome, Italy)
Lunch and Poster Display session (ID 48)
134P - Pathologic complete response according to the level of tumor-infiltrating lymphocytes and histologic grade in HR+HER2- breast cancer (ID 660)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Seung Ho Baek (Seoul, Korea, Republic of)
Lunch and Poster Display session (ID 48)
135P - Characteristics and Dosing Patterns of US Patients Diagnosed with HR+/HER2- Early Breast Cancer Initiating Abemaciclib at a Lower Dose than the Approved 150mg BID (ID 792)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Laura M. Spring (Boston, United States of America)
Lunch and Poster Display session (ID 48)
136P - Impact of Ovarian Stimulation on Breast Tumor Biology: First Results from a Pilot Study (ID 865)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- YASMINA Barral El Gaoui (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
137P - Adherence to and optimization of guidelines for Risk of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study (ID 621)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Una Kjällquist (Solna, Sweden)
Lunch and Poster Display session (ID 48)
138P - Predicted cumulative risk of late relapse in HR-positive/HER2-negative BC: a competing risk analysis of a real-world population. (ID 808)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Grazia M. Vernaci (Padua, Italy)
Lunch and Poster Display session (ID 48)
139P - Acceptance to Extend Hormonal Treatment Among Young Egyptian Breast Cancer Patients: A Questionnaire-Based Cross-Sectional Study. (ID 714)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Omnia M. Korani (Cairo, Egypt)
Lunch and Poster Display session (ID 48)
140P - Use of Chemotherapy and Loco-regional Therapy for Stage IA triple-negative Breast Cancer and their Association with Oncologic Outcomes: A Cancer Registry Study (ID 373)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Andre Pfob (Heidelberg, Germany)
Lunch and Poster Display session (ID 48)
141P - The Causes and Consequences of Incomplete Paclitaxel Administration during the Neoadjuvant treatment of Early Triple negative and HER2 positive breast cancer (CIPNETH) (ID 207)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Cedric Van Marcke (Woluwe-Saint-Lambert, Belgium)
Lunch and Poster Display session (ID 48)
142P - Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early stage triple negative breast cancer (eTNBC) (ID 935)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Alessia Lucia Daverio (Villejuif, Cedex, France)
Lunch and Poster Display session (ID 48)
143P - Sociodemographic Factors Associated with Adjuvant Chemotherapy Receipt in Stage I Triple Negative Breast Cancer (TNBC) (ID 895)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Candice N. Thompson (Stanford, United States of America)
Lunch and Poster Display session (ID 48)
144P - Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: a population-based study (ID 592)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Caroline E. Boman (Stockholm, Sweden)
Lunch and Poster Display session (ID 48)
145P - Impact of immunotherapy addition to dose density of neoadjuvant chemotherapy for triple negative breast cancer: a retrospective, real-world study from multiple centres in London, UK (ID 682)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mesel Veli (London, United Kingdom)
Lunch and Poster Display session (ID 48)
146P - Long-term outcomes of patients with triple negative breast cancer treated with adjuvant dose-dense sequential chemotherapy (ddsc): a Hellenic Cooperative Oncology Group (HeCOG) study (ID 772)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Elena Fountzilas (Thessaloniki, Greece)
Lunch and Poster Display session (ID 48)
147P - Racial bias in pretreatment MRI radiomics features to predict response to neoadjuvant systemic treatment in breast cancer. A Multicenter study in China, Germany, and the US (ID 560)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lie Cai (Heidelberg, Germany)
Lunch and Poster Display session (ID 48)
148P - The impact of chemotherapy relative dose intensity on pathological complete response and event-free survival in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. (ID 988)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Roberto Buonaiuto (Napoli, Italy)
Lunch and Poster Display session (ID 48)
149P - Risk of type 2 diabetes after breast cancer treatment: a 26-year population-based cohort study (ID 642)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Kasper Kjærgaard (Aarhus, Denmark)
Lunch and Poster Display session (ID 48)
150P - Diagnostic accuracy of MRI in tumour response evaluation after neoadjuvant chemotherapy in patients with different subtypes of breast cancer (ID 532)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lucia Vanovcanova (Bratislava, Slovak Republic)
Lunch and Poster Display session (ID 48)
151P - Exploring the Predictive Potential of [18F]FDG PET/CT for Pathological Complete Response to Neoadjuvant Therapy: A Prospective Study (ID 975)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Fabrizia Gelardi (Milan, Italy)
Lunch and Poster Display session (ID 48)
152P - Inflammatory BReast cancer (IBC) in low and mIDdle-income countries (LMICs): knowledGE, and practice patternS, The BRIDGES study (ID 375)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Ilana M. Schlam (Washington, United States of America)
Lunch and Poster Display session (ID 48)
153P - Correlation Between Disease Free Survival (DFS) Endpoints and Overall Survival (OS) in Elderly Patients with Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Early Breast Cancer (eBC) (ID 531)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mark E. Robson (New York, United States of America)
Lunch and Poster Display session (ID 48)
154P - Validation of PREDICT tool version 2.2 in early-stage breast cancer (BC) patients enrolled in adjuvant trials by the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo (MIG) (ID 854)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Roberto Borea (Genova, Italy)
Lunch and Poster Display session (ID 48)
155P - From Bench to Equity: Closing the Knowledge Gap on Racial Differences in TNBC Response to Immunotherapy (ID 376)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Oday Elmanaseer (Washington, United States of America)
Lunch and Poster Display session (ID 48)
156P - The impact of Ki-67 on prognosis and chemotherapy benefit in breast cancer patients with ER-positive/HER2-negative micrometastatic disease in sentinel lymph nodes: a register-based cohort study. (ID 940)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Eva Tegnelius (Orebro, Sweden)
Lunch and Poster Display session (ID 48)
157TiP - A Window-of-Opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC) (IBCSG 67-22; PREcoopERA) (ID 529)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Elisabetta Munzone (Milan, Italy)
Lunch and Poster Display session (ID 48)
158TiP - NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer (GIM31-Neo-AGILE trial) (ID 662)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Claudia Von Arx (Napoli, Italy)
Lunch and Poster Display session (ID 48)
159TiP - TROPION-Breast04: Phase (Ph) 3 study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2– breast cancer (BC) (ID 361)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sibylle Loibl (Neu-Isenburg, Germany)
Lunch and Poster Display session (ID 48)
160P - Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype (ID 427)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Elisa Agostinetto (Brussels, Belgium)
Lunch and Poster Display session (ID 48)
161P - Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families. (ID 791)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Maartje A. Schreurs (Rotterdam, Netherlands)
Lunch and Poster Display session (ID 48)
162P - The influence of BRCA1 large genomic rearrangements on the clinicopathological features and survival of patients with breast cancer (ID 1062)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Alejandro Aranda-Gutierrez (Monterrey, Mexico)
Lunch and Poster Display session (ID 48)
163P - Characterization of HER2-Low Breast Cancer in Young Women with Germline BRCA1/2 Pathogenetic Variants: Results of a Large International Retrospective Cohort Study (ID 258)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Francesco Schettini (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
164P - Incorporation of the Polygenic Risk Score (PRS) in breast cancer (BC) risk estimation among carriers of a Moderate Penetrance Pathogenic Variant (MPPV) (ID 574)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Maria A. Rezqallah Aron (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
165P - From Bench to Bedside: Functional Domains of BRCA Mutations for Personalized Medicine in Breast Cancer (ID 579)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Pablo Torres-Mozas (Jaén, Spain)
Lunch and Poster Display session (ID 48)
166P - Clinical use of tumor sequencing for identification of germline pathogenic variants (gPV) in breast cancer (BC): the SEQ project (ID 747)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mara Cruellas Lapena (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
167P - Exploring the role of rare germline variants in non-coding regions of cancer predisposition genes in triple-negative breast cancer patients (ID 1034)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Michela Palleschi (Meldola, Italy)
Lunch and Poster Display session (ID 48)
168P - Cardiovascular Risks in Breast Cancer: Insights from BRCA1/2 Mutation Carriers and Sporadic Cases (ID 846)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Panagiotis Mallios (Norrköping, Sweden)
Lunch and Poster Display session (ID 48)
169P - Radiomics Models for B-mode Breast Ultrasound and Strain Elastography for Breast Cancer Diagnosis (INSPiRED 005): An International, Multicenter Analysis (ID 547)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tanja He (Heidelberg, Germany)
Lunch and Poster Display session (ID 48)
170P - Clinico-pathological profile of women with breast arterial calcification on mammograms - Retrospective analysis of cardiac risk and malignant transformation (ID 331)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Simran Razdan (Hyderabad, India)
Lunch and Poster Display session (ID 48)
171P - A deep learning model for breast cancer diagnosis from fine-needle aspiration cytology whole slide images (ID 428)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Loïc Le Bescond (Villejuif, France)
Lunch and Poster Display session (ID 48)
172P - MicroRNAs in nipple aspirate fluid hold promise as a novel screening diagnostic for early breast cancer detection: results from a Dutch multicenter cross-sectional study (ID 601)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Laura A. De Rooij (Utrecht, Netherlands)
Lunch and Poster Display session (ID 48)
173P - Clinical Utility of piezoelectricity hand-held scanner towards breast texture changes and early tumor detection (ID 981)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Joana C. Gonçalves (Barreiro, Portugal)
Lunch and Poster Display session (ID 48)
174P - Modelling Cost-Effectiveness of breast cancer screening: Mammography leads to substantial cost savings for breast cancer treatment (ID 982)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Moira Rushton (Ottawa, Canada)
Lunch and Poster Display session (ID 48)
175P - Global burden, trends and risk factors of premenopausal breast cancer from 1990 to 2019 with prediction until 2039 (ID 466)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Cao B. Kun (Fuzhou, China)
Lunch and Poster Display session (ID 48)
176P - Age-adjusted trends of malignant breast hemangiosarcoma (ID 1026)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Amr S. Aly (Ismailia, Egypt)
Lunch and Poster Display session (ID 48)
177P - Rsults Of The Recent Nationwide Breast Cancer Screening In CAMEROON (ID 485)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- BLAISE NKEGOUM (YAOUNDE, Cameroon)
Lunch and Poster Display session (ID 48)
178TiP - The BRAVE study: a web-based prospective cohort and biological bank for unaffected BRCA1/2 Mutation Carriers (ID 368)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Eleonora Bruno (Milan, Italy)
Lunch and Poster Display session (ID 48)
185P - Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07) (ID 219)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Komal Jhaveri (New York, United States of America)
Lunch and Poster Display session (ID 48)
186P - Exploratory Pooled Safety Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients With HER2+ or HER2-low Unresectable and/or Metastatic Breast Cancer (mBC) in DESTINY-Breast Trials (ID 571)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Yeon Hee Park (Seoul, Korea, Republic of)
Lunch and Poster Display session (ID 48)
187P - Stage I results of a phase II study of datopotamab deruxtecan (Dato-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2) (ID 900)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Rupert Bartsch (Vienna, Austria)
Lunch and Poster Display session (ID 48)
188P - A Health-Related Quality-of-Life (HRQoL) Analysis From DESTINY-Breast04: Trastuzumab Deruxtecan (T-DXd) vs Capecitabine (CAP) in Patients (Pts) With Hormone Receptor–Positive (HR+), HER2-Low Metastatic Breast Cancer (mBC) (ID 572)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Naoto T. Ueno (Honolulu, United States of America)
Lunch and Poster Display session (ID 48)
189P - The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) from ASCENT (ID 614)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Laura García Estevez (Madrid, Spain)
Lunch and Poster Display session (ID 48)
190P - French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients (pts) with HER2+ metastatic or unresectable breast cancer (m/u BC): first results of REALITY-01 ambispective study (ID 793)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jean-Yves Pierga (Paris, CEDEX 5, France)
Lunch and Poster Display session (ID 48)
191P - Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study (ID 830)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Nadia Haddy (Saint-Denis Cedex, France)
Lunch and Poster Display session (ID 48)
192P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic HER2-positive breast cancer (ID 956)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Luca Visani (Firenze, Italy)
Lunch and Poster Display session (ID 48)
193P - Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials (ID 878)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Oleg Gluz (Mönchengladbach, Germany)
Lunch and Poster Display session (ID 48)
194P - Monitoring for pneumonitis due to trastuzumab deruxtecan (T-DXd); a single centre experience (ID 625)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Olivia Walker (London, United Kingdom)
Lunch and Poster Display session (ID 48)
195P - Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with HER2 positive advanced breast cancer: a multicentric Portuguese study (ID 931)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Rita C. Bizarro (Loures, Portugal)
Lunch and Poster Display session (ID 48)
196P - Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: data from five neoadjuvant studies (ID 790)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Fabienne Warnecke (Frankfurt am Main, Germany)
Lunch and Poster Display session (ID 48)
197P - Malignant Pleural Effusion derived metastatic breast cancer cells as an ex vivo model for personalized drug response (ID 929)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Zhanna Dauyey (Amsterdam, Netherlands)
Lunch and Poster Display session (ID 48)
198P - Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy After Induction With Pembrolizumab Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Patient-Reported Outcomes From KEYLYNK-009 (ID 905)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Antonio Llombart Cussac (Valencia, Spain)
Lunch and Poster Display session (ID 48)
199P - Adoptive PD1+ Tumor-Infiltrating Lymphocyte Therapy for Metastatic TNBC: First Results of the Safety Run-in Phase of the TILS001 Clinical Trial (ID 795)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Laura Angelats (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
200P - Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003 (ID 595)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Serafin Morales Murillo (Alpicat, Spain)
Lunch and Poster Display session (ID 48)
201P - The implementation of first-line pertuzumab and the impact on overall survival in patients with de Novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: a population-based cohort study (ID 296)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Nan Ding (Maastricht, Netherlands)
Lunch and Poster Display session (ID 48)
202P - Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: a SONABRE study (ID 643)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Nan Ding (Maastricht, Netherlands)
Lunch and Poster Display session (ID 48)
203P - Real-world treatment patterns in patients with HER2+ unresectable (u) or metastatic (m) breast cancer (BC): HER2 Real study final analysis in Asia-Pacific (APAC) and Brazil (ID 891)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Carlos H. Barrios (Porto Alegre, Brazil)
Lunch and Poster Display session (ID 48)
204P - Clinical features predictive of never-progressive disease to first-line anti-HER2 therapy: real-world data from the ESME national cohort (ID 520)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Thomas Grinda (Villejuif, Cedex, France)
Lunch and Poster Display session (ID 48)
205P - Trastuzumab biosimilar (TB) in combination with pertuzumab (P) and chemotherapy (CT) in Her2 positive, metastatic breast cancer (MBC) : efficacy and safety. (ID 969)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Gilles Freyer (Pierre-Bénite, CEDEX, France)
Lunch and Poster Display session (ID 48)
206P - Prognostic role of tumor-infiltrating lymphocytes (TILs) in first-line HER2-positive (HER2+) metastatic breast cancer (BC): a real-world study (ID 814)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Beatrice Taurelli Salimbeni (Milan, Italy)
Lunch and Poster Display session (ID 48)
207P - Sequential therapy with HER2 tyrosine kinase inhibitors in patients with HER2-positive metastatic breast cancer (ID 581)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Elena Shagisultanova (Aurora, United States of America)
Lunch and Poster Display session (ID 48)
208P - Clinicopathological factors and treatment management in HER2+ breast cancer patients with central nervous system metastasis (ID 616)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Ornella Ponzoni (Modena, Italy)
Lunch and Poster Display session (ID 48)
209P - Real-world effectiveness of palbociclib + endocrine therapy in HR+/HER2- Advanced Breast Cancer patients: Interim Results of the PERFORM study (ID 260)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Matthias Korell (Neuss, Germany)
Lunch and Poster Display session (ID 48)
210P - Prognostic value of HER2-low status in metastatic breast cancer (mBC) patients treated with I line CDK 4/6 inhibitors (CDK 4/6i): a real-word analysis of the GIM14/BIOMETA study (ID 431)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Chiara Molinelli (Genova, Italy)
Lunch and Poster Display session (ID 48)
211P - Drug-drug Interactions and their impact on clinical outcomes and adverse events in hormone receptor (HR)+/HER2- advanced breast cancer patients treated with ribociclib + letrozole: Insights from the BiotaLEE Trial (ID 589)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Andrea Botticelli (Rome, Italy)
Lunch and Poster Display session (ID 48)
212P - A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer (ID 411)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Virginia F. Borges (Aurora, United States of America)
Lunch and Poster Display session (ID 48)
213P - Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC). (ID 847)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Stefania Morganti (Boston, United States of America)
Lunch and Poster Display session (ID 48)
214P - Comparing Ribociclib versus Palbociclib as a second line treatment in combination with Fulvestrant in metastatic breast cancer. A randomised clinical trial. (ID 334)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Manar Hamed (Mansoura, Egypt)
Lunch and Poster Display session (ID 48)
215P - Impact of germline BRCA1/2 pathogenic variants on outcomes of HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: a systematic review and meta-analysis (ID 663)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Michele Bottosso (Padova, Italy)
Lunch and Poster Display session (ID 48)
216P - What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine?: Real-world data from the RIBANNA study (6th interim analysis (IA)) (ID 325)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Diana I. Lüftner (Brandenburg an der Havel, Germany)
Lunch and Poster Display session (ID 48)
217P - Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity (ID 596)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Chiara Benvenuti (Rozzano, Italy)
Lunch and Poster Display session (ID 48)
218P - Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b cohort results (ID 453)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Erika P. Hamilton (Nashville, United States of America)
Lunch and Poster Display session (ID 48)
219P - New prognostic factors in advanced HR+ HER2- breast cancer treated with CDK4/6 inhibitors (ID 465)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sonia Crocetti (Ancona, Italy)
Lunch and Poster Display session (ID 48)
220P - Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (ABC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial (ID 551)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Antonio Llombart-Cussarc (Barcelona, Spain)
Lunch and Poster Display session (ID 48)
221P - Incidence and survival after brain metastases among patients with stage I-III breast cancer: A population-based study (ID 818)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Rania Chehade (Toronto, Canada)
Lunch and Poster Display session (ID 48)
222P - Poor response to Cyclin Dependent Kinase 4/6 inhibition in metastatic inflammatory breast cancer (ID 583)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Azadeh Nasrazadani (Houston, United States of America)
Lunch and Poster Display session (ID 48)
223P - Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) Study (ID 289)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Seda Kahraman (Ankara, Turkey)
Lunch and Poster Display session (ID 48)
224P - Efficacy of Single-Agent Second Line Fulvestrant (FUL) in Metastatic Invasive Lobular Carcinoma (mILC) Exposed to First Line Aromatase Inhibitors (AI) and Cyclin-Dependent Kinase 4 and 6 inhibitors (CDK4/6is). (ID 603)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jason A. Mouabbi (Houston, United States of America)
Lunch and Poster Display session (ID 48)
225P - Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients (ID 679)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- María Luisa Sánchez-León (Seville, Spain)
Lunch and Poster Display session (ID 48)
226P - Prevalence and Characteristics of HR+/HER2- MBC with ESR1 Mutations Post-CDK Inhibitor Therapy (ID 816)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Roberta Scafetta (Rome, Italy)
Lunch and Poster Display session (ID 48)
227P - The role of CDK4/6 inhibitors in sequencing of endocrine treatment in metastatic breast cancer or can we accept the SONIA trial results in real-world practice? (ID 843)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Olesya Stativko (Moscow, Russian Federation)
Lunch and Poster Display session (ID 48)
228P - Comparison of Response with Chemotherapy vs Endocrine Therapy and its Association with Ki67 in Hormone Receptor Positive Metastatic Breast Cancer (ID 885)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sundas Rafique (Lahore, Pakistan)
Lunch and Poster Display session (ID 48)
229P - The influence of ethnicity on cyclin-dependent kinase inhibitors efficacy: a systematic review and meta-analysis (ID 927)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Roberto Buonaiuto (Napoli, Italy)
Lunch and Poster Display session (ID 48)
230P - HER2-low status in advanced breast cancer patients treated with CDK4/6 inhibitors: is it predictive of outcome? (ID 225)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Marcin Kubeczko (Warsaw, Poland)
Lunch and Poster Display session (ID 48)
232P - Assessment of treatment outcomes with Everolimus and Exemestane after CDK 4/6 inhibitors in hormone receptor positive metastatic breast cancer patients in Clatterbridge Cancer Centre, Liverpool. (ID 522)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Smriti Gaur (Liverpool, Haryana, United Kingdom)
Lunch and Poster Display session (ID 48)
233P - Real world first line (1L) treatment selection for Australian patients (pts) with hormone receptor positive advanced breast cancer (HR+ ABC) (ID 744)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Vanessa Wong (Ballarat, Australia)
Lunch and Poster Display session (ID 48)
234P - A retrospective analysis to assess the impact of interaction between CDK4/6 inhibitors and proton pump inhibitors on clinical outcomes in metastatic breast cancer patients. (ID 874)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Maitreyee Rai (Pittsburgh, United States of America)
Lunch and Poster Display session (ID 48)
235P - Advancing Treatment Choices: CDK4/6 Inhibitor Switching in HR+/HER2- Metastatic Breast Cancer (ID 395)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Paola Zagami (Milan, Italy)
Lunch and Poster Display session (ID 48)
236P - Survival outcomes of patients (pts) with metastatic lobular breast cancer (mLBC) receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): a retrospective analysis (ID 821)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Grazia Castellano (Milan, Italy)
Lunch and Poster Display session (ID 48)
237P - Overall survival (OS) estimation using target trial emulation of major randomized controlled trials (RCTs) with the ESME metastatic breast cancer (MBC) real-world data (RWD) (ID 918)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Alison Antoine (Lyon, France)
Lunch and Poster Display session (ID 48)
238P - Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovativeness, trials, endpoints, and price (ID 359)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Julia Caroline Michaeli (Munich, Germany)
Lunch and Poster Display session (ID 48)
239P - Genomic landscape of metastatic ER+/HER2- breast cancer (BC) with loss of estrogen (ER) and/or progesterone (PR) receptor (ID 756)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Ilenia Migliaccio (Firenze, Italy)
Lunch and Poster Display session (ID 48)
240P - Age at diagnosis and survival in metastatic breast cancer (MBC) (ID 849)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Kristen D. Brantley (Boston, United States of America)
Lunch and Poster Display session (ID 48)
241P - Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer- Multi-Institutional Retrospective Cohort Study in Japan- (ID 537)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Reiko Mitsueda (Kagoshima, Japan)
Lunch and Poster Display session (ID 48)
242P - An artificial intelligence (AI)-based model to predict conversion from HER2-0 primary breast cancer (BC) to HER2-low phenotype at relapse (ID 781)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Federica Miglietta (Padova, Italy)
Lunch and Poster Display session (ID 48)
243P - Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An All-Ireland Patient-led Survey (CTRIAL-IE 23-05) (ID 326)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Catherine Weadick (Cork, Ireland)
Lunch and Poster Display session (ID 48)
244P - Identifying Metastatic Breast Cancer in Northern Ireland using Machine Learning Algorithms and Cancer Registry data – development and validation. (ID 873)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Damien Bennett (Belfast, United Kingdom)
Lunch and Poster Display session (ID 48)
245P - Antitumor–Protumor Ratio as an Important Prognostic Biomarker in Metastatic Triple-Negative Breast Cancer: A Multicenter Cohort Study (ID 327)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Jeffry B. Tenggara (South Jakarta, Indonesia)
Lunch and Poster Display session (ID 48)
246P - Clinical Utility of Molecular Tumor Board in Metastatic Breast Cancer (ID 706)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Antonio Marra (Milan, Italy)
Lunch and Poster Display session (ID 48)
247P - Financial and time burden associated with living with a metastatic breast cancer (MBC) diagnosis in Ireland – An all-Ireland patient-led survey (CTRIAL-IE 23-05). (ID 552)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Rachel Keogh (Dublin, Ireland)
Lunch and Poster Display session (ID 48)
248P - Uncovering insensitive platitudes: A survey of people with metastatic breast cancer (MBC) (ID 448)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Joanne Taylor (Manchester, United Kingdom)
Lunch and Poster Display session (ID 48)
249P - Efficacy and tolerability of Low Dose Metronomic Chemotherapy using Capecitabine and Cyclophosphamide in Metastatic Breast Cancer. (ID 487)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Karolina Larsson (Göteborg, Sweden)
Lunch and Poster Display session (ID 48)
250P - Evolution of characteristics, real-world (rw) treatment (tx) landscape, and survival outcomes in patients (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) in the United States (ID 615)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Kevin Punie (Antwerpen, Belgium)
Lunch and Poster Display session (ID 48)
251P - Genomic alterations of breast cancer patients with leptomeningeal disease: a retrospective analysis (ID 736)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Louis Larrouquere (Lyon, France)
Lunch and Poster Display session (ID 48)
252P - Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase 3 randomized trials (RCT) in metastatic breast cancer (MBC). (ID 859)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Yael Berner Wygoda (Jerusalem, Israel)
Lunch and Poster Display session (ID 48)
253P - Patient-Centric Approach: Examining Quality-of-Life Incorporation in 5-Year Phase III Metastatic Breast Cancer Trials (ID 688)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Shreyas Kalantri (Louisville, United States of America)
Lunch and Poster Display session (ID 48)
254P - Development of Machine Learning models for the prediction of early progression (EP) to first line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). (ID 741)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sergio Pannunzio (Rome, Italy)
Lunch and Poster Display session (ID 48)
255P - A study to compare the response of conventional chemotherapy plus metformin versus conventional chemotherapy in non-diabetic metastatic breast cancer. (ID 770)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Aqsa Rauf (Lahore, Pakistan)
Lunch and Poster Display session (ID 48)
256P - Clinical Significance of Grade in Triple Negative Breast Cancer (ID 858)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Haniya Farooq (Dublin, Ireland)
Lunch and Poster Display session (ID 48)
257P - A low fT3/fT4 ratio as a negative prognostic factor in patients with metastatic breast cancer (ID 785)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Roberta Scafetta (Rome, Italy)
Lunch and Poster Display session (ID 48)
258P - Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France (ID 824)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Mario Campone (Saint-Herblain, CEDEX, France)
Lunch and Poster Display session (ID 48)
259P - Analysis of Survival Outcomes in Breast Cancer Patients with Brain Metastases: A Comprehensive Study Utilizing the National Cancer Database (ID 1040)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Vivek Podder (Miami, United States of America)
Lunch and Poster Display session (ID 48)
260P - LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer (ID 604)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Salvador Blanch (Valencia, Spain)
Lunch and Poster Display session (ID 48)
261TiP - TROPION-Breast05: Phase (Ph) 3 study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) (ID 362)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Peter Schmid (London, United Kingdom)
Lunch and Poster Display session (ID 48)
262TiP - PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (ID 371)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Manfred K. Welslau (Aschaffenburg, Germany)
Lunch and Poster Display session (ID 48)
263TiP - IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs (IMPORTANT trial) – a pragmatic randomized-controlled trial (ID 458)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Antonis Valachis (Eskilstuna, Sweden)
Lunch and Poster Display session (ID 48)
264TiP - TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ID 488)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Melinda L. Telli (Stanford, United States of America)
Lunch and Poster Display session (ID 48)
265TiP - SOLTI-2201 ACROSS-TROP2 trial – A phase II study to identify predictive biomarkers of Sacituzumab Govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer (ID 635)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Eva M. Ciruelos (Madrid, Spain)
Lunch and Poster Display session (ID 48)
272P - Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial – The ADAPT Study (ID 317)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Noelle Vrancken Peeters (Amsterdam, Netherlands)
Lunch and Poster Display session (ID 48)
273P - Experiences and preferences about information on treatment (tx)-related side effects (SE) among patients (pts) with early breast cancer (EBC) (ID 769)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Antonio Di Meglio (Villejuif, Cedex, France)
Lunch and Poster Display session (ID 48)
274P - Efficacy of surgical gloves (SG) as compression therapy versus frozen gloves (FG) to prevent paclitaxel-induced peripheral neuropathy (PN): the trial ELEGANT (ID 974)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Aurélia JOUREAU-CHABERT (Lyon, France)
Lunch and Poster Display session (ID 48)
275P - Clinical and socioeconomic risk factors of prolonged opioid use after breast cancer: A Danish population-based study (ID 279)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Kirsten M. Woolpert (Aarhus, Denmark)
Lunch and Poster Display session (ID 48)
276P - Pitfalls and consequences of insufficient data recording of patient reported outcomes (PROs) in metastatic breast cancer trials (ID 217)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Can M. Ünal (Cologne, Germany)
Lunch and Poster Display session (ID 48)
277P - Descriptive analysis of hepatic safety for patients (pts) with HR+/HER2− breast cancer (BC) treated with ribociclib (RIB) + endocrine therapy (ET) (ID 613)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Nadia Harbeck (Munich, Germany)
Lunch and Poster Display session (ID 48)
278P - Exploring Quality of Life in Women with Early Breast Cancer: A Multi-Center Cross-Sectional Study (ID 943)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Ana Dugonjic Okrosa (Zagreb, Croatia)
Lunch and Poster Display session (ID 48)
279P - Incidence, risk factors and management of medication-related osteonecrosis of the jaw in breast cancer patients treated with Zoledronic Acid or Denosumab over a 5-year period in a UK tertiary institution (ID 436)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Oyeyemi Akala (Leicester, United Kingdom)
Lunch and Poster Display session (ID 48)
280P - Outcomes of Women With Early-Stage Triple Negative Breast Cancer (TNBC) in Connection With Age and Other Socio-demographic Factors: A Population Based Cohort Study (ID 575)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Shahid Ahmed (Saskatoon, Canada)
Lunch and Poster Display session (ID 48)
281P - Psychological distress in parents with cancer and its association with parenting concerns, self-efficacy and emotion regulation – A cross sectional questionnaire study (ID 345)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Maria Romare Strandh (Uppsala, Sweden)
Lunch and Poster Display session (ID 48)
282P - Metabolic Syndrome and Survival in Breast Cancer Survivors: A Systematic Review and Meta-Analysis (ID 365)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Helene Borup (Aarhus, Denmark)
Lunch and Poster Display session (ID 48)
283P - Navigating Sexuality and Hormone Therapy in Early Luminal Breast Cancer (ID 573)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tiago A. Pina Cabral (Lisbon, Portugal)
Lunch and Poster Display session (ID 48)
284P - Risk Assessment for Systemic Recurrence in HER2-Low Breast Cancer: Evaluating Hormone Receptors and Immunohistochemical Profiles (ID 618)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Victor Baylon-Valdez (Chihuahua, Mexico)
Lunch and Poster Display session (ID 48)
285P - Survivorship care plans and recurrence detection in breast cancer patients (ID 634)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Lorenzo Belluzzi (Modena, Italy)
Lunch and Poster Display session (ID 48)
286P - Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project (ID 467)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Anna Amela Valsecchi (Torino, Italy)
Lunch and Poster Display session (ID 48)
287P - Clinico-pathological features and survival outcome of Inflammatory breast cancer: An Indian Scenario (ID 526)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Ajay Gogia (New Delhi, India)
Lunch and Poster Display session (ID 48)
289P - Evaluation of breast skin/nipple-areolar complex sensation and quality of life after nipple-sparing mastectomy followed by reconstruction (ID 342)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Beatriz S. Polita (Riga, Latvia)
Lunch and Poster Display session (ID 48)
290P - Adverse events (AEs) and impact on quality of life (QoL) of antibody-drug conjugates (ADC) in the treatment of metastatic breast cancer (mBC): a systematic review and meta-analysis of randomized controlled trials (RCTs) (ID 407)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Marta Perachino (Genova, Italy)
Lunch and Poster Display session (ID 48)
291P - Perceptions of Antibody Drug Conjugate (ADC)-induced Nausea and Vomiting: Results of a Survey of Healthcare Providers at ESMO (ID 606)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Giampaolo Bianchini (Milan, Italy)
Lunch and Poster Display session (ID 48)
292P - Association between Adverse Childhood Events and Baseline Cognitive Functioning in Patients with Localized Breast Cancer. (ID 664)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Ayelet Shai (Haifa, Israel)
Lunch and Poster Display session (ID 48)
293P - Evaluating Chemotherapy Side Effects in Moroccan Breast Cancer Patients and Introducing an AI Mobile Health App for Remote Support: A Comprehensive Approach (ID 735)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Farah Choulli (Marrakech, Morocco)
Lunch and Poster Display session (ID 48)
294P - Breast cancer patient driven research agenda developed for and by breast cancer patients (ID 238)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Marjolein Scholten (Utrecht, Netherlands)
Lunch and Poster Display session (ID 48)
295P - Climate Change Impact and Sustainability: A survey of Breast International Group (BIG) Members (ID 619)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Seamus O'Reilly (Cork, Cork, Ireland)
Lunch and Poster Display session (ID 48)
296P - Management of the sexual dysfunction in breast cancer survivor women on adjuvant therapy (ID 612)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Sophio Khundadze (Tbilisi, Georgia)
Lunch and Poster Display session (ID 48)
297P - Modified Delphi Consensus on Interventions for Radiation Dermatitis in Breast Cancer: A Canadian Expert Perspective (ID 845)
Lecture Time
12:00 - 12:00
Session Name
Room
Exhibition area
Date
Thu, 16.05.2024
Time
12:00 - 13:00
Speakers
- Tarek Hijal (Montreal, Canada)